Barbui, Tiziano
Ghirardi, Arianna
Masciulli, Arianna
Carobbio, Alessandra
Palandri, Francesca http://orcid.org/0000-0001-8367-5668
Vianelli, Nicola
De Stefano, Valerio http://orcid.org/0000-0002-5178-5827
Betti, Silvia
Di Veroli, Ambra
Iurlo, Alessandra
Cattaneo, Daniele
Delaini, Federica
Bonifacio, Massimiliano
Scaffidi, Luigi
Patriarca, Andrea http://orcid.org/0000-0003-4415-2906
Rumi, Elisa http://orcid.org/0000-0002-7572-9504
Casetti, Ilaria Carola
Stephenson, Clemency
Guglielmelli, Paola http://orcid.org/0000-0003-1809-284X
Elli, Elena Maria
Palova, Miroslava
Bertolotti, Laura
Erez, Daniel
Gomez, Montse
Wille, Kai
Perez-Encinas, Manuel
Lunghi, Francesca
Angona, Anna
Fox, Maria Laura
Beggiato, Eloise
Benevolo, Giulia
Carli, Giuseppe
Cacciola, Rossella
McMullin, Mary Frances
Tieghi, Alessia
Recasens, Valle http://orcid.org/0000-0001-5129-8597
Marchetti, Monia
Griesshammer, Martin
Alvarez-Larran, Alberto
Vannucchi, Alessandro Maria http://orcid.org/0000-0001-5755-0730
Finazzi, Guido
Funding for this research was provided by:
Novartis
Amgen Foundation
Celgene
Bayer
Amgen
Janssen Pharmaceuticals
Gilead Sciences
Article History
Received: 23 January 2019
Revised: 4 April 2019
Accepted: 8 April 2019
First Online: 29 May 2019
Compliance with ethical standards
:
: TB has been a speaker and consultant for Novartis and he has received research grant from AOP Orphan. VDS has received consulting and lecture fees from Amgen, Celgene, Novartis, and institutional research grants from Bayer and Novartis. MLF has been a member of advisory Board for Novartis and she has received travel grants from the company. MFM has been a speaker and consultant for Novartis. MM has received honoraria for advisory boards and lectures at sponsored meetings from Celgene, Amgen, Janssen, Gilead, Novartis. AMV has been a speaker for Novartis, Celgene, and Shire and participated to advisory boards of Celgene, Incyte, Novartis. The remaining authors declare that they have no conflict of interest.